← Browse by Condition
Medical Condition
ras mutation
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1
NCT06229340 Phase 2
Recruiting
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Enrollment
20 pts
Location
Russia
Sponsor
N.N. Petrov National Medical R...
NCT06299839 Phase 1
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
Enrollment
48 pts
Location
United States, Bulga...
Sponsor
Pasithea Therapeutics Corp.
NCT07252479 Phase 1
Recruiting
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Enrollment
91 pts
Location
United States
Sponsor
Adlai Nortye Biopharma Co., Lt...